Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Guduchi (Tinospora cordifolia / Giloy) is a classical Ayurvedic adaptogen and immunomodulator used for fever, infections, and general immunity. It is generally well tolerated. Several case reports have linked commercial Giloy preparations — particularly those adulterated with Tinospora sinensis — to acute liver injury; always use authentic, tested sources. It may enhance the effects of hypoglycaemic medications. Avoid during pregnancy and lactation. Immune-stimulating properties warrant caution in autoimmune conditions.
Biological and Chemical Classification
- Scientific Name
- Tinospora cordifolia
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Guduchi indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:10
Evidence Distribution
-
Observational / other LOW evidence YELLOWEditorial: Cancer prevention and therapy using herbal formulations of natural immune modulators. ↗Kumar V et al.. Editorial: Cancer prevention and therapy using herbal formulations of natural immune modulators.. Front Immunol. 2026. PMID:41890725.PMID 41890725 ↗Journal Front ImmunolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41890725/
-
Observational / other LOW evidence YELLOWHarnessing the potential of selected Himalayan species for phyto-cosmeceutical formulations guided through biochemometric analysis. ↗Singh B et al.. Harnessing the potential of selected Himalayan species for phyto-cosmeceutical formulations guided through biochemometric analysis.. Sci Rep. 2026. PMID:41565943.PMID 41565943 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41565943/
-
Observational / other LOW evidence YELLOWAcute and subacute toxicity evaluation of a polyherbal blend in rats. ↗Murudkar PH et al.. Acute and subacute toxicity evaluation of a polyherbal blend in rats.. Drug Chem Toxicol. 2026. PMID:41521415.PMID 41521415 ↗Journal Drug Chem ToxicolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41521415/
-
Observational / other LOW evidence YELLOWDiketopiperazines from the Endophytic Streptomyces triticiradicis TTCF1 (Tinospora cordifolia): Isolation and Evaluation of Antibacterial and Anticancer Properties. ↗Taechowisan T et al.. Diketopiperazines from the Endophytic Streptomyces triticiradicis TTCF1 (Tinospora cordifolia): Isolation and Evaluation of Antibacterial and Anticancer Properties.. Pak J Biol Sci. 2025. PMID:41618675.PMID 41618675 ↗Journal Pak J Biol SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41618675/
-
Observational / other LOW evidence YELLOWGB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology. ↗Das A et al.. GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology.. BMC Complement Med Ther. 2025. PMID:41382285.PMID 41382285 ↗Journal BMC Complement Med TherYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41382285/
-
Observational / other LOW evidence YELLOWInvestigation of nutritional and phytochemical properties of wild medicinal plant species. ↗Kumari M et al.. Investigation of nutritional and phytochemical properties of wild medicinal plant species.. Sci Rep. 2025. PMID:41366271.PMID 41366271 ↗Journal Sci RepYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41366271/
-
Observational / other LOW evidence YELLOWExploring the anticancer potential of Tinospora cordifolia with computational insights into EGFR inhibition. ↗Asha G et al.. Exploring the anticancer potential of Tinospora cordifolia with computational insights into EGFR inhibition.. In Silico Pharmacol. 2025. PMID:41357420.PMID 41357420 ↗Journal In Silico PharmacolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41357420/
-
Observational / other LOW evidence YELLOWEffects of herbal medicines in combating antimicrobial resistance and its impacts on public health. ↗Rodrigues JSSP et al.. Effects of herbal medicines in combating antimicrobial resistance and its impacts on public health.. Braz J Biol. 2025. PMID:41259467.PMID 41259467 ↗Journal Braz J BiolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41259467/
-
Observational / other LOW evidence YELLOWAnalysis of suspected serious adverse drug reactions reported with traditional medicines from the United Nations Asia region in WHO vigibase. ↗N C et al.. Analysis of suspected serious adverse drug reactions reported with traditional medicines from the United Nations Asia region in WHO vigibase.. BMC Complement Med Ther. 2025. PMID:41219814.PMID 41219814 ↗Journal BMC Complement Med TherYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41219814/
-
Observational / other LOW evidence YELLOWAyurvedic management of a chronic venous ulcer using dusting of powdered botanicals - A Case Report. ↗Sisodia AS et al.. Ayurvedic management of a chronic venous ulcer using dusting of powdered botanicals - A Case Report.. J Ayurveda Integr Med. 2025. PMID:41207143.PMID 41207143 ↗Journal J Ayurveda Integr MedYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41207143/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Guduchi. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Guduchi
A score of 3.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.